Cerebral cortex dose sparing for glioblastoma patients: IMRT versus robust treatment planning

To date, patients with glioblastoma still have a bad median overall survival rate despite radiation dose-escalation and combined modality treatment. Neurocognitive decline is a crucial adverse event which may ...

http://ift.tt/2GVlTvc